Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
R-MTX-zanbrutinib in Secondary CNS Lymphoma

Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of retrospective

  • 0 views
  • 17 Jun, 2022
  • 1 location
  • 0 views
  • 25 Oct, 2021
  • 1 location
Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

This phase Ib/II trial is evaluating the efficacy and side effect of orelabrutinib and sintilimab as possible treatments for relapsed or refractory central nervous system lymphoma.

  • 0 views
  • 23 Jul, 2021
  • 1 location
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or …

whole-brain radiotherapy
lenalidomide
cancer
maintenance treatment
temozolomide
  • 0 views
  • 13 May, 2022
  • 35 locations
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous

antibiotics
progressive disease
lymphoid leukemia
proteasome inhibitor
large b-cell lymphoma
  • 721 views
  • 13 May, 2022
  • 16 locations
Tisagenlecleucel In Primary CNS Lymphoma

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel.

neutrophil count
anticoagulants
platelet count
ibrutinib
methotrexate
  • 0 views
  • 24 Feb, 2022
Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.

serum bilirubin
diffuse large b-cell lymphoma
b-cell lymphoma
methotrexate
initial diagnosis
  • 1 views
  • 22 Mar, 2022
  • 1 location
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.

  • 10 views
  • 26 Apr, 2022
  • 7 locations
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (OptiMATe)

This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.

  • 0 views
  • 14 Mar, 2022
  • 1 location
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a

  • 0 views
  • 01 Jul, 2022
  • 4 locations